🇺🇸 FDA
Patent

US 9023356

Treatment method using EGFR antibodies and SRC inhibitors and related formulations

granted A61KA61K31/506A61K31/517

Quick answer

US patent 9023356 (Treatment method using EGFR antibodies and SRC inhibitors and related formulations) held by The Regents of the University of California expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/506, A61K31/517, A61K39/39541, A61K45/06